Bar Harbor BioTechnology

BRB, which is also developing similar tests for other cancers and autoimmune diseases, has partnered with lab testing services firm Clinical Reference Laboratory for clinical validation of its tests.

The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.

In an interview with PCR Insider, Greg Shipley, director of the Quantitative Genomics Core Laboratory at University of Texas Health Science Center at Houston, discussed the technique and how UTHSCH researchers are using it.

BHB, founded in 2006, is betting that the new service offering will generate both new revenues and additional sales of its StellARray and XenoQ plate-based PCR kits.

Bar Harbor Biotechnology will offer real-time PCR services to researchers using its StellARrays and XenoQ assays.

Lonza is distributing Bar Harbor BioTechnology's new tools under an exclusive agreement.

Product Watch

Premium

Bar Harbor's XenoQ assays

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.